Lyra Therapeutics, Inc.
Bioresorbable self-expanding stent for pediatric pulmonary artery stenosis
- Sector
- Medtech
- Headquarters
- MA
- Founded
- 2005
- Latest Form D
- $50M, Jun 2023
- Total capital
- $256M
- Federal grants
- $8.6M
- 6 awards · 2016–2018
- Rank in peer group#56 of 538
- Private capital raised
- $247M
- 13 Form D · last Jun 2023
- 41 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 10
- 21 pending · first 2020
- Rank in peer group#61 of 538
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 13th filing$50M
- Private capital raisedForm D · SEC · 12th filing$100M
- Private capital raisedForm D · SEC · 11th filing$28M
- Federal grantHealth and Human S · Phase II · Novel Bioabsorbable, Flexible Polymeric Stent for Pulmonary Artery Stenosis$926K
- Federal grantHealth and Human S · Phase II · Novel Bioabsorbable, Flexible Polymeric Stent for Pulmonary Artery Stenosis$946K
- Private capital raisedForm D · SEC · 10th filing$6M
- Federal grantHealth and Human S · Phase II · Novel Bioabsorbable, Flexible Polymeric Stent for Pulmonary Artery Stenosis$2.9M
- Private capital raisedForm D · SEC · 9th filing$18M
- Private capital raisedForm D · SEC · 8th filing$5.1M
- Private capital raisedForm D · SEC · 7th filing$3M
- Private capital raisedForm D · SEC · 6th filing$12M
- Private capital raisedForm D · SEC · 5th filing$3M
- Private capital raisedForm D · SEC · 4th filing$10.1M
- Private capital raisedForm D · SEC · 3rd filing$1M
- Private capital raisedForm D · SEC · 2nd filing$2M
- Private capital raisedForm D · SEC · 1st filing$8.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
3 records have no date or no amount, so they aren’t placed on the timeline.
Standing among 538 peers
Line = medianMedtech · Device
- Federal grants#56 · top 10%
- Granted patents#61 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ann MerrifieldDirectorNamed in SEC Form D filings
- Bradford SmithDirectorNamed in SEC Form D filings
- C. Ann MerrifieldDirectorNamed in SEC Form D filings
- C. Ann MerrifieldDirectorNamed in SEC Form D filings
- Don ElseyExecutive OfficerNamed in SEC Form D filings
- Edward AndersonDirectorNamed in SEC Form D filings
Show all 20 people
- George WhitesidesDirectorNamed in SEC Form D filings
- Harlan Waksal, M.D.Executive Officer, DirectorNamed in SEC Form D filings
- James R. TobinDirectorNamed in SEC Form D filings
- James R. TobinDirectorNamed in SEC Form D filings
- Jason CavalierExecutive OfficerNamed in SEC Form D filings
- John Bishop, Ph.D.Executive OfficerNamed in SEC Form D filings
- Konstantin PoukalovDirectorNamed in SEC Form D filings
- Maria Palasis, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Michael AltmanDirectorNamed in SEC Form D filings
- Nancy Snyderman, M.D., FACSDirectorNamed in SEC Form D filings
- Richard Nieman, M.D.Executive OfficerNamed in SEC Form D filings
- Robert LangerDirectorNamed in SEC Form D filings
- W. Bradford SmithDirectorNamed in SEC Form D filings
- W. Bradford SmithDirectorNamed in SEC Form D filings
What it has protected
USPTO · 10 granted of 31- GrantedDrug-eluting Medical ImplantsUSPTOUS 12,697,420
- GrantedImplantable Scaffolds For Treatment Of SinusitisUSPTOUS 12,564,659
- GrantedScaffold Loading And Delivery SystemsUSPTOUS 12,336,923
Show all 31 patent records
- Drug-eluting Medical ImplantsAug 4, 2026 · US 12,697,420Granted
- Implantable Scaffolds For Treatment Of SinusitisMar 3, 2026 · US 12,564,659Granted
- Scaffold Loading And Delivery SystemsJun 24, 2025 · US 12,336,923Granted
- Implantable Scaffolds For Treatment Of SinusitisDec 12, 2024 · Application 18810072Pending
- Implantable Scaffolds For Treatment Of SinusitisOct 31, 2024 · Application 18769827Pending
- Implantable Scaffolds For Treatment Methods Of SinusitusAug 20, 2024 · US 12,064,339Granted
- Implantable Matrix For Treating Central Nervous System DisordersAug 15, 2024 · Application 18615515Pending
- Implantable Scaffolds For Treatment Of SinusitisJul 16, 2024 · US 12,036,337Granted
- Implantable Scaffolds For Treatment Of SinusitusFeb 22, 2024 · Application 18497519Pending
- Implantable Corticosteroid Matrix For Sinus ConditionFeb 8, 2024 · Application 18235449Pending
- Scaffold Loading And Delivery SystemsNov 9, 2023 · Application 18199195Pending
- Assessing The Response To Treatment Of SinusitisAug 10, 2023 · Application 18114522Pending
- Osmotic Drug Delivery ImplantsJul 27, 2023 · Application 18127214Pending
- Implantable Scaffolds For Treatment Of Sinusitis And Method Of Reducing InflammationMay 23, 2023 · US 11,654,213Granted
- Implantable Matrix For Treating Central Nervous System DisordersMar 30, 2023 · Application 17567406Pending
- Scaffold Loading and Delivery SystemsJun 10, 2021 · Application 17113516Pending
- Scaffold Loading and Delivery SystemsApr 13, 2021 · US 10,973,664Granted
- Implantable Scaffolds For Treatment Of SinusitisDec 15, 2020 · US 10,864,298Granted
- Scaffold Loading and Delivery SystemsDec 8, 2020 · US 10,857,013Granted
- Implantable Scaffolds for Treatment of SinusitusOct 20, 2020 · US 10,806,568Granted
- Drug-eluting Medical ImplantsJul 23, 2020 · Application 16842390Pending
- Osmotic Drug Delivery ImplantsApplication PCTUS2021052331Pending
- Assessing The Response To Treatment Of SinusitisApplication 63074283Pending
- Implantable Corticosteroid Matrix For Sinus ConditionApplication 63251159Pending
- Implantable Corticosteroid Matrix For Sinus ConditionApplication 63271972Pending
- Implantable Corticosteroid Matrix For Sinus ConditionApplication PCTUS2022019379Pending
- Implantable Corticosteroid Matrix For Sinus ConditionApplication 63181594Pending
- Implantable Matrix For Treating Central Nervous System DisordersApplication PCTUS2022044555Pending
- Implantable Corticosteroid Matrix For Sinus ConditionApplication 63158017Pending
- Assessing The Response To Treatment Of SinusitisApplication PCTUS2021048911Pending
- Implantable Corticosteroid Matrix For Sinus ConditionApplication 63241224Pending
Related companies, and why
- MICROGEN, LLCSimilar federal contract value in Medtech · null in contracts
- ETA DIAGNOSTICS, INC.Similar federal contract value in Medtech · null in contracts
- ASSIST EQUIPMENT DEVELOPMENT, INC.Similar federal contract value in Medtech · null in contracts
- INOVASC, LLCSimilar federal contract value in Medtech · null in contracts
- MONOD BIO, INC.Similar federal contract value in Medtech · null in contracts
- Cylerus, Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .